Research
- Access to all necessary nuclear and GMP facilities
- Nuclear R&D and operational expertise
- Partnership representing the full expertise and capabilities
Our research focuses on the development of new radiopharmaceutical products, based on the availability of both high potential medical isotopes and dedicated nuclear infrastructure. We aim for products with a high possibility of adding value to nuclear medicine, more specifically for cancer treatment.
- Medical isotope in high demand
- Beta-emitter
- Independent supply from in-house FIELD-LAB process
- High quality
- Chemotherapeutic compound (cisplatin) with Pt-195m integrated by synthesis
- For in-human use
- Chemotherapeutic function unaltered
- Single alpha emitting during decay
- Ideal half-life (~10 hrs.)
- Reliable supply
Lead-212
Pb-212 is a medical isotope with great perspective for cancer therapy; the isotope offers maximal efficiency and minimal side effects.
Pb-212 has a half-life of 11 hours: long enough for targeting purposes, short enough and with a single alpha-emission to avoid long term, off-target damage.
Pb-212 production is complex and is difficult to get access to. FIELD-LAB has managed to achieve unlimited availability by developing its own, in-house production process. In addition, FIELD-LAB operates the facilities autonomously making it flexible in assigning resources and using this high potential isotope for R&D purposes.
Read more
Pt-195m CISSPECT
Pt-195m CISSPECT is a promising imaging agent to measure the distribution of cisplatin chemotherapy in the patient. It can possibly be used to predict the effectivity of cisplatin treatment and/or to determine potential toxicity.
The prediction outcome can then serve as input to optimise the individual patient treatment and to determine whether cisplatin treatment is useful. Or if alternatives should be considered, due to expected severe side effects such as kidney failure, loss of hearing, nausea and tiredness.
Read More
Lu-177 chloride n.c.a.
Currently, Lu-177 is dominating the clinical pipeline regarding the innovation of radiopharmaceuticals. Researchers have found numerous possible applications for this radio isotope.
We are looking to provide bio pharma and scientific partners with Lu-177 chloride (n.c.a.) and support their pre-clinical and clinical studies in the development of Lu-177 radiopharmaceuticals. These partners can range from (academic) hospitals to commercial start-ups.
Read more
Through FIELD-LAB you can...
Articles
Already in 2001, NRG supported the development of Peptide Receptor Radionuclide Therapy with carrier added Lutetium-177 (Lu-177 c.a.) by the supply of Lutetium-177 trichloride as a radiochemical. Nowadays, Lu-177 no carrier added is preferably used. “Lu-177 n.c.a. has a higher specific activity and thus radiolabeling efficiency, than lu-177 c.a.”, according to Marion Chomet, lead scientist at FIELD-LAB. Chomet and her colleagues are now fine-tuning and finalizing their custom made lutetium-177 n.c.a. process. But there are several challenges and practical considerations that they are facing.
It is game on for actinium-225 and lead-212. These two alpha-emitters can treat the same cancer and they are center stage in several researches around the world. However, only one can be the winner and conquer the market. What are the differences between these two powerhouses and which one is more likely to take the prize.